Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

• Status: Recruiting
• Trial end date: 2021-09-15
• Target enrollment: 0
• Participant gender: All

Summary

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Optall Vision
• Treatments: Brimonidine Tartrate; Bromfenac; Hyaluronic Acid; Oxymetazoline; Phenylephrine; Pilocarpine

Criteria

Inclusion Criteria:

• Healthy

• Presbyopic

• 40 - 60 years

Exclusion Criteria:

• Diabetics

• Previous eye surgery

• Previous eye disease

• > 0.50 myopia

• > 1.5 hyperopia or astigmatism